Published in Neurology Journal Scan / Research · June 29, 2024 Epilepsia
TAKE-HOME MESSAGE
- Cannabidiol-enriched oil (CBDO) can reduce the risk of seizures in some patients with drug-resistant epilepsy but may worsen seizure control in others. In this study involving 19 patients treated with ≈260-mg CBDO and ≈12-mg THC daily, pre- and post-treatment evaluations for seizures, gait, cognition, mood, sleep, and electrophysiological changes were performed. Overall, 43.75% of the patients responded to CBDO, with an average reduction of 82.4% in seizure frequency, and 56.25% noted an average seizure frequency increase of 30.1%. Response to CBDO was associated with no clear baseline clinical or electrophysiological characteristics. Responders showed improved dual-task walking and MoCA scores.
- Multiple forms of cannabidiol are available, and questions about their use are common in epilepsy practice. This small trial provides some insights into CBDO use, suggesting that it could improve seizures but also has the potential of worsening the seizure control. Based on these initial data and lack of other evidence regarding CBDO use in patients with epilepsy, probably avoiding CBDO use may be the best approach till more controlled trials are available.
Commentary: Of course, this above recorded experimenting with this revisiting of non-trialled self-medicating ‘Charlotte’s Web’ tinctures in a non-pharmaceutical configuration is not necessary as GW Pharma (now JAZZ Pharmaceutical) conducted the thorough and exhaustive clinical trials, manufactured and had registered their product for a genre of non-cannabis drug resistance epilepsy labelled Epidiolex ® In this context, these new ‘trials’ are not only redundant, but a little concerning if best-practice pharmaceutical health is still valued.
(For complete research - Source: Practice Update)
